ATE441406T1 - Verbesserung der bildqualität im auge - Google Patents

Verbesserung der bildqualität im auge

Info

Publication number
ATE441406T1
ATE441406T1 AT05759460T AT05759460T ATE441406T1 AT E441406 T1 ATE441406 T1 AT E441406T1 AT 05759460 T AT05759460 T AT 05759460T AT 05759460 T AT05759460 T AT 05759460T AT E441406 T1 ATE441406 T1 AT E441406T1
Authority
AT
Austria
Prior art keywords
image quality
mind
improved image
zeaxanthin
mixtures
Prior art date
Application number
AT05759460T
Other languages
German (de)
English (en)
Inventor
John Barbur
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Application granted granted Critical
Publication of ATE441406T1 publication Critical patent/ATE441406T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/10Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Eye Examination Apparatus (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
AT05759460T 2004-06-29 2005-06-08 Verbesserung der bildqualität im auge ATE441406T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04015189 2004-06-29
PCT/EP2005/006168 WO2006002735A1 (en) 2004-06-29 2005-06-08 Improvement of image quality in the eye

Publications (1)

Publication Number Publication Date
ATE441406T1 true ATE441406T1 (de) 2009-09-15

Family

ID=35782481

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05759460T ATE441406T1 (de) 2004-06-29 2005-06-08 Verbesserung der bildqualität im auge

Country Status (9)

Country Link
US (2) US20080045605A1 (enExample)
EP (1) EP1761254B1 (enExample)
JP (1) JP5074184B2 (enExample)
KR (1) KR20070027649A (enExample)
CN (1) CN101094666B (enExample)
AT (1) ATE441406T1 (enExample)
DE (1) DE602005016405D1 (enExample)
ES (1) ES2331083T3 (enExample)
WO (1) WO2006002735A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006084687A1 (en) * 2005-02-11 2006-08-17 Dsm Ip Assets B.V. Use of zeaxanthin for the treatment of diseases of the peripheral retina
AT503329A1 (de) * 2006-03-02 2007-09-15 Omnica Gmbh Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6218436B1 (en) * 1993-06-28 2001-04-17 The Howard Foundation Pharmaceutically active carotenoids
US5382714A (en) * 1994-03-17 1995-01-17 The Catholic University Of America Process for isolation, purification, and recrystallization of lutein from saponified marigold oleoresin and uses thereof
US5827652A (en) * 1995-10-31 1998-10-27 Applied Food Biotechnology, Inc. Zeaxanthin formulations for human ingestion
FR2749758B1 (fr) * 1996-06-12 1998-08-07 Oenobiol Sa Lab Composition a activite bronzante et photoprotectrice et ses applications esthetiques
WO1997048388A1 (en) * 1996-06-17 1997-12-24 The Board Of Trustees Of The University Of Illinois Method of retarding and ameliorating central nervous system and eye damage
US6075058A (en) * 1998-12-12 2000-06-13 Tufts University Compositions for increased bioavailability of carotenoids
US6712466B2 (en) * 2001-10-25 2004-03-30 Ophthonix, Inc. Eyeglass manufacturing method using variable index layer
ES2299687T3 (es) * 2002-01-30 2008-06-01 Dsm Ip Assets B.V. Luteina/zeaxantina para la proteccion contra el encandilamiento.
CN1481804A (zh) * 2002-12-17 2004-03-17 无锡杰西医药科技有限公司 防治白内障、黄斑变性等眼病的配方及其使用方法

Also Published As

Publication number Publication date
CN101094666A (zh) 2007-12-26
JP2008505137A (ja) 2008-02-21
EP1761254A1 (en) 2007-03-14
US20080045605A1 (en) 2008-02-21
CN101094666B (zh) 2010-09-29
WO2006002735A1 (en) 2006-01-12
KR20070027649A (ko) 2007-03-09
EP1761254B1 (en) 2009-09-02
DE602005016405D1 (de) 2009-10-15
ES2331083T3 (es) 2009-12-21
US20110172313A1 (en) 2011-07-14
JP5074184B2 (ja) 2012-11-14

Similar Documents

Publication Publication Date Title
IL172700A (en) Methods for making neutralizing and cross-activating antibodies against kir2dl and drugs that include them for use in assessing antibody toxicity
WO2012038512A3 (en) Composition comprising sod, lutein and zeaxanthin
WO2012125830A3 (en) Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control
PE20050255A1 (es) Nuevas cianotiazolidas y procedimiento para su preparacion como medicamentos
CL2008000806A1 (es) Compuestos derivados de aza piridopirimidinona, con actividad agonista de hm74a; procedimiento de preparacion de dichos compuestos; composicion farmaceutico que las comprende; y su uso para preparar medicamentos para el tratamiento de enferemedades ateroscleroticas, dislipidemias, alzheimer, diabetes, entre otras.
EA201001283A1 (ru) Комбинация витамина d и 25-гидроксивитамина d3
CY1108794T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου
NO20075540L (no) Lignian-inneholdende sammensetninger
MY208400A (en) Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof
WO2018169282A3 (ko) Atpif1을 함유하는 당뇨 치료용 약학조성물
DK2111125T3 (da) Flydende formuleringer indeholdende carotinoider
EA201201239A1 (ru) Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением
PH12019500949A1 (en) Ror-gamma modulators
MX2007001943A (es) Nuevos compuestos biaromaticos activadores de los receptores del tipo receptor activado del proliferador de peroxisoma (ppar) y su uso en composiciones cosmeticas o farmaceuticas.
Musa et al. Nutritional Factors: benefits in glaucoma and ophthalmologic pathologies
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
MX2019003725A (es) Glicinato de metformina, composiciones farmaceuticas que comprenden la misma, y metodos de uso de la misma.
Feng et al. Cytoprotective effect of lacritin on human corneal epithelial cells exposed to benzalkonium chloride in vitro
WO2015048503A3 (en) N-arylmethyl sulfonamide negative modulators of nr2a
CL2012002942A1 (es) Uso de un derivado sintetico de retinol e hidroxianisol butilado disuelto en aceite de soya para preparar un medicamento util en el tratamiento de un sujeto humano que sufre de la perdida o el deterioro de la vison causado por un trastorno por deficencia de retinol 11-cis producido endogenamente; composicion farmeceutica.
WO2020142607A3 (en) Uv screening and antioxidant composition and use thereof
ATE441406T1 (de) Verbesserung der bildqualität im auge
Ahn et al. Tat-ATOX1 inhibits streptozotocin-induced cell death in pancreatic RINm5F cells and attenuates diabetes in a mouse model
WO2012143857A8 (en) Combination of carotenoid, phytooestrogen and vitamin c for moisturizing the skin
PH12022550938A1 (en) Products and methods using sonication to increase bioactivity of soy peptides

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties